The US Food and Drug Administration appears comfortable with the idea of approving US WorldMeds, LLC’s new drug application for eflornithine (DFMO) in high-risk neuroblastoma based upon the results from an externally controlled trial, with animal data as confirmatory evidence.
Such an approval would be groundbreaking. FDA review staff said the agency has not previously relied upon a single, externally...